Oppenheimer Assumes Alpine Immune Sciences at Outperform, Announces Price Target of $14
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Mark Breidenbach assumes Alpine Immune Sciences (NASDAQ:ALPN) with an Outperform rating and announces a price target of $14.
June 26, 2023 | 10:51 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer assumes Alpine Immune Sciences with an Outperform rating and a price target of $14.
The Outperform rating and $14 price target by Oppenheimer analyst Mark Breidenbach indicate a positive outlook for Alpine Immune Sciences. This news is likely to have a positive impact on ALPN's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100